EU approves Otsuka's long-acting HAE drug Dawnzera An EMA nod for Otsuka's Dawnzera offers EU patients with HAE a drug that can be self-administered by patients with up to eight weeks between doses.

#hereditaryangioedema #Otsuka #Ionis #Dawnzera #regulatoryapproval #Rarediseases #pharmanews #HAEdrug #Dawnzera #antisenseoligonucleotidebasedplasmaprekallikreininhibitor #PKKinhibitor #plasmaprekallikreininhibitor #PKK #EMA #HAEpatients #clinicaltrials #RNAtargetedtherapy
zurl.co/Zw7sM

The #EuropeanCommission has approved #Otsuka's #Dawnzera for the prevention of recurrent attacks in #raredisease hereditary angioedema (#HAE), a drug that can be self-administered by patients with weeks between doses.

pharmaphorum.com/news/eu-appr...

#hereditaryangioedema #HAE #chronicillness #Dawnzera #donidalorsen #raredisease #preventivecare #BioNews #AngioedemaNews

Orsini's Exclusive Partnership with Ionis for Groundbreaking DAWNZERA Medication Orsini has been named the exclusive specialty pharmacy partner for Ionis Pharmaceuticals' new drug, DAWNZERA, aimed at treating hereditary angioedema.

Orsini's Exclusive Partnership with Ionis for Groundbreaking DAWNZERA Medication #United_States #Elk_Grove_Village #Ionis_Pharmaceuticals #Orsini_Pharmacy #DAWNZERA